The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol

Basic and Clinical Pharmacology and Toxicology

Volumn 101, Issue 5, 2007, Pages 350-358

  Hellum, Bent H ^a,b   Nilsen, Odd Georg ^b  

^a Medical Technical Research Center Trondheim   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; COMPLEMENTARY DNA; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; HERBACEOUS AGENT; QUINIDINE; VALERIAN;

AESCULUS HIPPOCASTANUM; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; DEMETHYLATION; DRUG ISOLATION; DRUG METABOLISM; ECHINACEA PURPUREA; GINKGO BILOBA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERICUM PERFORATUM; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

BIOTRANSFORMATION; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; ENZYME INHIBITORS; ETHANOL; HUMANS; KINETICS; PLANT EXTRACTS; PLANT PREPARATIONS; QUINIDINE;

AESCULUS; ECHINACEA PURPUREA; GINKGO BILOBA; VALERIANA OFFICINALIS;

EID: 34848906016     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00121.x     Document Type: Article

References (59)

1. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998 280 : 1569 75.
2. Rossler W, Lauber C, Angst J et al. The use of complementary and alternative medicine in the general population: results from a longitudinal community study. Psychol Med 2007 37 : 73 84.
3. Crawford NW, Cincotta DR, Lim A, Powell CV. A cross-sectional survey of complementary and alternative medicine use by children and adolescents attending the University Hospital of Wales. BMC Complement Altern Med 2006 6 : 16.
4. De Smet PA. Herbal remedies. N Engl J Med 2002 347 : 2046 56.
5. Hu Z, Yang X, Ho PC et al. Herb-drug interactions: a literature review. Drugs 2005 65 : 1239 82.
6. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002 32 : 451 78.
7. Gonzalez FJ, Tukey RH. Drug metabolism. In : Brunton LL, Lazo JS, Parker KL (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 2005 429 59.
8. Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci 2006 256 : 287 93.
9. Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991 41 : 23 6.
10. Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 1995 274 : 1611 3.
11. Usia T, Iwata H, Hiratsuka A, Watabe T, Kadota S, Tezuka Y. CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants. Phytomedicine 2006 13 : 67 73.
12. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000 378 : 356 63.
13. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002 71 : 1579 89.
14. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999 65 : L209 14.
15. Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007 100 : 23 30.
16. Gurley BJ, Gardner SF, Hubbard MA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005 77 : 415 26.
17. Gurley BJ, Gardner SF, Hubbard MA et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004 76 : 428 40.
18. Gurley BJ, Gardner SF, Hubbard MA et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005 22 : 525 39.
19. Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000 67 : 3103 12.
20. Chang TK, Chen J, Lee WB. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 2001 299 : 874 82.
21. Usia T, Watabe T, Kadota S, Tezuka Y. Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. Biol Pharm Bull 2005 28 : 1021 4.
22. Subehan, Usia T, Kadota S, Tezuka Y. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum. Planta Med 2006 72 : 527 32.
23. Silverman RB. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology. CRC Press, Boca Raton, FL, 1988 1 30.
24. Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998 26 : 207 15.
25. Easterbrook J, Lu C, Sakai Y, Li AP. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 2001 29 : 141 4.
26. Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998 26 : 1 4.
27. Busby WF Jr., Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 1999 27 : 246 9.
28. Ramamoorthy Y, Tyndale RF, Sellers EM. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 2001 11 : 477 87.
29. York JL. Enzymes: classification, kinetics and control. In : Devlin TM (ed.). Textbook of Biochemistry with Clinical Correlations. Wiley-Liss Inc., New York, 1997 127 78.
30. Otton SV, Brinn RU, Gram LF. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab Dispos 1988 16 : 15 7.
31. von Bahr C, Spina E, Birgersson C et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 1985 34 : 2501 5.
32. McLaughlin LA, Paine MJ, Kemp CA et al. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. J Biol Chem 2005 280 : 38617 24.
33. Bonifacio A, Keizers PH, Commandeur JN et al. Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy. Biochem Biophys Res Commun 2006 343 : 772 9.
34. Madani S, Paine MF, Lewis L, Thummel KE, Shen DD. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 1999 16 : 1199 205.
35. Prueksaritanont T, Dwyer LM, Cribb AE. (+)-bufuralol 1′- hydroxylation activity in human and rhesus monkey intestine and liver. Biochem Pharmacol 1995 50 : 1521 5.
36. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005 11 : 433 9.
37. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004 11 : 98 104.
38. Gorski JC, Huang SM, Pinto A et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004 75 : 89 100.
39. abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 1999 27 : 770 5.
40. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004 18 : 2273 81.
41. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, bul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother 2000 34 : 1013 6.
42. Durr D, Stieger B, Kullak-Ublick GA et al. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000 68 : 598 604.
43. Markowitz JS, Donovan JL, DeVane CL et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003 290 : 1500 4.
44. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000 294 : 88 95.
45. de los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St. John's wort. Am J Health Syst Pharm 2002 59 : 545 7.
46. Komoroski BJ, Zhang S, Cai H et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004 32 : 512 8.
47. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's wort (Hypericum perforatum) on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000 66 : 133 9.
48. Sorensen LB, Sorensen RN, Miners JO, Somogyi AA, Grgurinovich N, Birkett DJ. Polymorphic hydroxylation of perhexiline in vitro. Br J Clin Pharmacol 2003 55 : 635 8.
49. Munafo A, Buclin T, Tuto D, Biollaz J. The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. Eur J Clin Pharmacol 1992 43 : 441 3.
50. Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000 23 : 509 32.
51. Donovan JL, DeVane CL, Chavin KD et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004 32 : 1333 6.
52. Subehan, Usia T, Iwata H, Kadota S, Tezuka Y. Mechanism-based inhibition of CYP3A4 and CYP2D6 by Indonesian medicinal plants. J Ethnopharmacol 2006 105 : 449 55.
53. Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A. Mechanism-based inactivation of CYP2D6 by ethylenedioxymethamphetamine. Drug Metab Dispos 2004 32 : 1213 7.
54. Sadaba B, Lopez de OA, Azanza JR, Quiroga J, Cienfuegos JA. Concurrent clarithromycin and cyclosporin A treatment. J Antimicrob Chemother 1998 42 : 393 5.
55. Greenblatt DJ, von Moltke LL, Harmatz JS et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998 64 : 278 85.
56. Laine K, Tybring G, Hartter S et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001 70 : 327 35.
57. LLerena A, Berecz R, De La RA, Fernandez-Salguero P, Dorado P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 2001 23 : 616 20.
58. Dalen P, Dahl M, Andersson K, Bertilsson L. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Br J Clin Pharmacol 2000 49 : 180 4.
59. Moffat AC, Osselton MD, Widdop B. Clarke's Analysis of Drugs and Poisons, 3rd edn. Pharmaceutical Press, London, 2004.